Aleafia steps-up battle against opioid crisis
V.ALEF | 3 hours ago
Aleafialaunches new opiate replacement program; hits the gas on 1,000-patient opioid-reduction study.
TORONTO, April 4, 2018 - Aleafia Health Inc. (TSX-V-ALEF) announced that it launched a new opiate replacement program across its 23 Aleafia/Canabo clinic network.
As the opioid health-crisis continues across North America, Aleafia believes that its new initiativeputs it ahead of the curve in the battle against this life-destroying epidemic.
In light of new studies released by the American Medical Association that suggest cannabis may play a role in reducing some patients’ need for opioids, Aleafia`s opiate replacement program is designed to; :
Increase the pace of Aleafia`s previously announced 1,000-patient study on the use of medical cannabis to reduce opioid addiction that is currently underway,
Conduct extensive outreach to local and regional patients and physicians announcing Aleafia/Canabo program to substitute opioids with medical cannabis, and
Boost clinic education initiatives about the potential positive outcomes of replacing opioids with medical cannabis within Aleafia’s patient-focused, physician-led and research-based environment.
“While the problem of chronic opiate use is now well-identified, more work is needed to find solutions,” said Aleafia director, Dr. Michael Verbora. “Initial data from our opiate research study shows promise that cannabinoids can replace some—or all—of a patient’s opiate prescription when being used for chronic, non-cancer pain. We are keen to continue helping the millions of Canadians on opiates to consider replacing with cannabinoid therapy.”
Aleafia believes that it is uniquely positioned to have a meaningful role in the battled against opioids, which killed an estimated 4,000 Canadians in 2017, and kills an estimated 90 Americans per day. With a 40,000-strong physician-referred patient-base, and up to 1,500 additional patients joining the clinic network each month, Aleafia has the capacity to conduct large-scale studies on opioid reduction, as well as be a force for good in the education and awareness of medical practitioners across the country.
“From the very beginning, our goal at Aleafia was to provide evidence-based support for patients and their caregivers by introducing an effective alternative to the dangerous opioid option,” added Aleafia directorGary Goodyear “Today, we are ably positioned to make a meaningful difference with a large team of cannabinoid medicine experts, an established, cross-country clinic infrastructure, a much-sought-after, lucrative observational database, and an ambitious plan to grow our knowledge into more targeted, effective strains of medical cannabis for our patients.
|
1 |
... |
28 |
29 |
30 |
|
32 |
33 |
34
Thread abonnieren
